腹腔热灌注化疗、体外射频深部热疗、免疫治疗三位一体综合治疗在晚期卵巢癌中的临床应用

To Explore the Effect of Trinity Comprehensive Treatment Including Abdominal Cavity Perfusion Chemotherapy, RF Deep Thermal Therapy and the Immune Therapy in the Treatment of Advanced Ovarian Cancer

目的评价腹腔热灌注化疗联合体外射频深部热疗、免疫治疗三位一体综合治疗在晚期卵巢癌中的临床应用。方法将我科收治晚期上皮性卵巢癌患者42例作为研究对象。将其随机分为综合治疗组和腹腔化疗组。分析两组腹水控制率、治疗后KPS评分、CA125半衰期、骨髓抑制发生率。结果 42例病人均完成全部6疗程化疗,两组观察指标分别是:腹水控制率(90.9%:75.0%),治疗后KPS评分比较(31.8%:60.0%);CA125半衰期(17.3±5.1)天、(13.4±4.5)天;骨髓抑制发生率(18.2%:40.0%)。结论 "腹腔热灌注化疗结合联合体外射频深部热疗、免疫治疗"三位一体的综合治疗治疗晚期卵巢癌能显著提高腹水控制率、提高治疗KPS评分、缩短CA125半衰期、减少骨髓抑制发生率,而且能提高机体免疫力、促进造血功能恢复,是治疗晚期卵巢癌的一种有效的治疗手段,可提高晚期卵巢癌病人的生存率和生活质量。

Objective To evaluate the effect of the trinity comprehensive treatment including the peritoneal cavity hot perfusion chemotherapy, the deep in vitro rf heat therapy and the immune therapy of the treatment for the patients with advanced ovarian cancer. Methods 42 cases of patients with advanced epithelial ovarian cancer in our department were selected as the research object. The patients were randomly divided into treatment group and intraperitoneal chemotherapy group. The indicators including the ascites control, KPS score after treatment, CA125 half-life and the incidence of bone marrow suppression were analyzed. Results 42 cases of patients had complete 6 courses of chemotherapy. The results of the indicators were： control of ascites（90.9%： 90.9%）, KPS score comparison after treatment（31.8%： 60.0%）, CA125 half-life（17.3 ＋/- 5.1 days, 13.4 ＋/- 4.5 days） and the incidence of bone marrow suppression（18.2%： 40.0%）. Conclusion The trinity comprehensive therapy ＂Hot perfusion chemotherapy combined with abdominal cavity with deep in vitro rf heat therapy, immune therapy＂ in the treatment of advanced ovarian cancer can significantly improve the ascites control, increase the KPS score, shorten the CA125 half-life and reduce the incidence of bone marrow suppression. This method can improve the body immunity, promote hemopoietic function which is a kind of effective treatment for advanced ovarian cancer. It can improve the survival rate and life quality of advanced ovarian cancer patients.